BCR-ABL-IN-3 is a highly effective, irreversible inhibitor of Bcr-Abl, with an IC50 value of ≤100 nM for Ba/F3 Bcr-Abl T3151, displaying significant anti-cancer activity.

BCR-ABL (T3151, Ba/F3 cells):≤100 nM (IC50)

BCR-ABL-IN-3, also known as compound 7, administered at a dose of 15 mg/kg twice daily for 19 days, demonstrated significant antitumor effects in 7-8 week-old female NOD/SCID mice, each weighing 21.8 g and implanted with Ba/F 3 Bcr-Abl T3151 cells[1]. Additionally, in 7-8 week-old male Sprague Dawley rats weighing 210 g, BCR-ABL-IN-3 displayed pharmacokinetic properties with a maximum concentration (C max) of 5485 ng/mL and an area under the curve (AUC) of 5450 h·ng/mL, when administered intravenously (IV) at a dose of 2 mg/kg or orally (PO) at 20 mg/kg[1].